Republicans Eye Taxes on Employer Health Plans
Senate Republicans working on a healthcare bill are considering raising billions of dollars in revenue through a tax on employer-sponsored insurance plans. According to The Wall Street Journal, under current law health insurance is tax exempt and previous attempts to change the law have failed. The proposal is likely to face strong resistance, as in the past, and could raise taxes on millions of people.
Global Cost of Cancer Treatment
In the last 5 years, the global cost of cancer treatments has grown annually by 8.7%. However, the rising cost of treating cancer isn’t just about rising drug prices, according to Fierce Pharma. New oncology treatments bring better outcomes, which means patients taking them are living longer and staying on therapy longer. Two-thirds of the growth in cancer costs can be attributed to new drugs that have improved survival. The United States accounts for 46% of the world’s oncology costs.
After Surviving an Opioid Overdose
The majority of people who survive an opioid overdose go back to using the drugs, so some states are sending recovery coaches to the hospital to meet overdose survivors, reported The Pew Charitable Trusts. Recovery coaches inform overdose survivors of the resources available to help them quit and how they can reduce the risk of another overdose if they keep using. In some states, they might distribute naloxone kits and train survivors and friends and family on how to use them.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More